United Kingdom: medical cannabis available from November 1
The British Home Office has finalized the draft regulations governing cannabis-based medicines. They were developed in collaboration with the Advisory Council on the Misuse of Drugs (ACMD), the Chief Medical Officer, and a panel of independent experts tasked with pressure from civil society. These regulations were recently presented to both houses of Parliament and will take effect on November 1.
«Special» medications»
We had already explained in detail in a previous article Details of these regulations: They include an official definition of cannabis-based medicines as well as specific channels for access. These products are considered «special» medicines and fall under the existing legal framework governing the supply of unlicensed medicines to patients with exceptional needs. They may only be produced or imported by a manufacturer or seller that has obtained a license from the national drug regulatory agency and has complied with the applicable production standards.
This specific procedure, governed by Regulation 2001, also stipulates that these drugs may only be made available under the following conditions:
- a prescription from a specialist physician listed in the General Medical Council’s registry.
- clinical trials designed to test an experimental product.
- a marketing authorization approved by the national drug regulatory agency.
In short, access to cannabis-based medications will be phased in gradually and will remain extremely restrictive. The reason is that cannabis itself remains classified under Schedule Schedule 1 and is therefore not prescribed as is. It will therefore not be approved as a pain reliever, as is sometimes the case in the United States. The products will be transferred from the Schedule 1 to Schedule 2 subject to the granting of licenses by the national regulatory agency and, therefore, as scientific research progresses. The drugs in the Schedule 1 are available upon special request to the Ministry of the Interior, but only in exceptional cases.
The official document specifies that these regulations are not an end in themselves, but that the ACMD will conduct a long-term review of medical cannabis in parallel. The National Institute for Health and Care will be responsible for advising and training practitioners on medical cannabis. Meanwhile, the government will study the impact of this policy and develop a database.
-
Business4 weeks ago
Cronos Completes the Acquisition of CanAdelaar for 57.5 million euros
-
Cannabis in Quebec3 weeks ago
Cannabis: What France Could Learn from Quebec, Eight Years After Legalization
-
Cannabis in New Zealand3 weeks ago
Chronic Pain: New Zealand Is Testing Cannabis to Improve Sleep
-
Cannabis in France3 weeks ago
Dr. Pascal Douek, a tireless advocate for medical cannabis in France, has died
-
Cannabis in France3 weeks ago
Medical cannabis: The Greens introduce two amendments to accelerate its widespread adoption
-
Cannabis in Spain4 weeks ago
Spain: Medical Cannabis Is Coming to About 50 Hospitals
-
Business4 weeks ago
British patients now have access to THCV-rich cannabis flowers
-
Cannabis in Canada3 weeks ago
A Canadian study reveals the pleasant psychotropic effects of high-dose CBD


You must be logged in to post a comment Login